Delving into the Latest Updates on Genistein sodium dihydrate(Axcentua Pharmaceuticals AB) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Genistein crystalline, genistein sodium salt dihydrate, genistein-SSDH

+ [3]

Target

ERβ

Mechanism

ERβ modulators(Estrogen receptor beta modulators)

Therapeutic Areas

NeoplasmsCongenital DisordersDigestive System Disorders+ [3]

Active Indication

Mucopolysaccharidosis IIIPancreatic Cancer

Inactive Indication

Adenocarcinoma

Originator Organization

Axcentua Pharmaceuticals AB

Active Organization

Axcentua Pharmaceuticals AB

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

RegulationOrphan Drug (EU)

Login to view timeline

Structure

Molecular FormulaC15H10O5

InChIKeyTZBJGXHYKVUXJN-UHFFFAOYSA-N

CAS Registry446-72-0

View All Structures (2)

In this paper we present methodological and experimental details and results from an OECD Test Guideline 474 and GLP-compliant in vivo micronucleus study on sodium molybdate dihydrate in Sprague Dawley rats. Prior to the conduct of this study, there was a data-gap for reliable in vivo genotoxicity data for molybdenum substances. The presentation of the new study is complemented by a review of other available in vitro and in vivo data on the genotoxicity of molybdenum substances, focussing on substances where the contained or released molybdate ion, MoO₄^2-, is considered the responsible moiety for any toxicological effect (grouping/category approach). After consideration of the relevance and reliability of all available data, the absence of a concern for genotoxicity of molybdate in vitro and in vivo is concluded.

01 Jul 2024·Journal of Endodontics

Pain Reduction of Ibuprofen Sodium Dihydrate Alone and in Combination with Acetaminophen in an Untreated Endodontic Pain Model: A Randomized, Double-blind Investigation

Article

Author: Palya, Morgan ; Drum, Melissa ; Ni, Andy ; Nusstein, John ; Chevere, Janine Matos ; Reader, Al ; Fowler, Sara

INTRODUCTIONMost pain studies have been based on a postsurgical, third molar model using ibuprofen (IBU)/acetaminophen (APAP). Studies have found quicker onset of pain relief with a newer formulation of IBU - ibuprofen sodium dihydrate (ISD). The purpose of this study was to compare pain reduction of ISD/APAP to ISD in an acute endodontic pain model of untreated patients experiencing moderate to severe pain with symptomatic apical periodontitis.METHODS AND MATERIALSIn this double-blind randomized study, 64 adult emergency patients in acute moderate to severe pain, a pulpal diagnosis of symptomatic irreversible pulpitis or necrosis, and symptomatic apical periodontitis participated. Each patient randomly received either one dose of 768 mg ISD/1000 mg APAP or one dose of 768 mg ISD. Pain intensity scores were recorded every 15 minutes over 240 minutes using the Heft-Parker VAS along with time to first sign of pain relief, time to meaningful pain relief, and time to 50% pain relief also recorded. The data were analyzed statistically.RESULTSBoth ISD and ISD/APAP groups showed a progressive decrease in pain from baseline to 120 minutes after medication administration. Afterward, a relative plateau was seen in the patients' pain. There was no difference in the VAS scores between the ISD and ISD/APAP at any given time point, time to first sign of pain relief, time to meaningful pain relief, and time to 50% pain relief.CONCLUSIONSThe addition of APAP to ISD for pain control in an untreated endodontic pain model did not differ significantly from ISD alone.

17 Apr 2024·Natural Product Research

New butanolide derivatives from the marine derived fungus Aspergillus terreus GZU-31-1 by chemical epigenetic manipulation

Article

Author: Chen, Xiaocong ; Tang, Yuqian ; Zhou, Yuwei ; Cui, Hui ; Liu, Yena ; Zhao, Zhongxiang

Chemical epigenetic manipulation of Aspergillus terreus GZU-31-1 led to the discovery of five butanolide derivatives (1-5), including two new ones (1 and 2), and four known diphenyl ether derivatives (6-9). Compound 1 featured a Z-configuration double bond in the isoprenyl group was a potential anti-inflammatory bioactive group. Compound 2 was a new natural product. Moreover, compound 3 with a deacetylated group at C-4 was rarely reported as a butanolide analogue, which was isolated from the liquid culture treated with polyketide pathway inhibitor sodium citrate dihydrate. All of the isolates (1-9) were tested for their anti-inflammatory effects on the production of nitric oxide in lipopolysaccharide-induced microglial cells (RAW 264.7 cells). Compounds 1, 7, 8 and 9 exhibited more potent anti-inflammatory activity with IC₅₀ values of 16.31, 20.16, 9.53 and 21.64 μM than the positive control (indomethacin, IC₅₀, 24.0 μM).

100 Deals associated with Genistein sodium dihydrate(Axcentua Pharmaceuticals AB)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma	Phase 3	SE	Axcentua Pharmaceuticals AB	01 Nov 2010
Mucopolysaccharidosis III	Phase 2	-	Axcentua Pharmaceuticals AB	-
Pancreatic Cancer	Phase 2	-	Axcentua Pharmaceuticals AB	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


732 (AUA2011)	Phase 2	Metastatic Prostate Carcinoma	-	Genistein treatment	dtjhbezxdd(yscllizcoj) = giuiqqnmni sgncvejjyv (vkgmmemzza, +/ - 1.0) View more	-	01 Apr 2011